Engineered immune cells target the root of severe autoimmune illnesses
NCT ID NCT06614270
Summary
This early-stage study is testing a new cell therapy for people with severe autoimmune diseases that haven't responded to standard treatments. Doctors will collect immune cells from umbilical cord blood, modify them in a lab to target a specific protein (CD19) on harmful immune cells, and infuse them back into patients. The main goals are to see if this approach is safe and if it can help control diseases like lupus, scleroderma, and vasculitis.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the second affiliated hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.